Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus.

European review for medical and pharmacological sciences·2018
Same author

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

A Gradient-Based Approach for Breast DCE-MRI Analysis.

BioMed research international·2018
Same author

A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B.

Alimentary pharmacology & therapeutics·2018
Same author

Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review.

Journal of viral hepatitis·2018

Related Experiment Video

Updated: Jul 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Short-duration therapy for hepatitis C: suitable for all?

A Mangia1

  • 1Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy. a.mangia@tin.it

Journal of Viral Hepatitis
|March 27, 2007
PubMed
Summary

Peginterferon alpha (PegIFN alpha) and ribavirin therapy for chronic hepatitis C (HCV) can be shortened. Early viral clearance predicts sustained virological response (SVR), allowing for reduced treatment durations.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Jul 16, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Peginterferon alpha (PegIFN alpha) plus ribavirin is a standard treatment for chronic hepatitis C virus (HCV).
  • Standard treatment durations are 48 weeks for genotypes 1 and 4, and 24 weeks for genotypes 2 and 3.
  • Treatment side effects and cost necessitate exploring shorter therapeutic regimens.

Purpose of the Study:

  • To review existing evidence on shortened treatment durations for chronic hepatitis C.
  • To evaluate the relevance and limitations of studies investigating reduced treatment periods.
  • To discuss the predictive value of early viral clearance for sustained virological response (SVR).

Main Methods:

  • Review of published studies on PegIFN alpha plus ribavirin therapy for HCV.
  • Analysis of data correlating early viral clearance with SVR rates.
  • Consideration of treatment duration adjustments based on HCV genotype and viral load.

Main Results:

  • Fast and persistent viral clearance, particularly a negative HCV RNA at week 4, is a strong predictor of SVR.
  • Shortened treatment durations (12-16 weeks for genotypes 2/3, 24 weeks for genotype 1) are being investigated based on early viral clearance.
  • Current international guidelines recommend 48 or 24 weeks based on genotype.

Conclusions:

  • Early viral clearance is a key factor in optimizing hepatitis C treatment duration.
  • Further research is needed to address open issues regarding shortened PegIFN alpha plus ribavirin regimens.
  • Optimizing treatment duration can potentially mitigate side effects and reduce therapy costs.